International Psoriasis Council

Advancing Knowledge. Improving Care.

Welcoming Our Newest IPC Councilors: Leaders in Psoriasis Treatment and Research

Join us in welcoming IPC’s newest Councilors: Christopher Bunick, Jeffrey Cohen, Giovanni Damiani, Victoria Guillano, Renata Magalhães, Eingun James Song, and Yi Xiao. Recently appointed and selected by the IPC Board of Directors, these experts are dedicated to enhancing global research on psoriasis and improving patient care.

As IPC Councilors, they will leverage their expertise to advance IPC initiatives in research, treatment, and education on a global scale, aligning with our commitment to improving the health and well-being of people with psoriasis worldwide. We invite you to learn more about these psoriasis experts through their biographies and discover how they contribute to our mission of enhancing patient outcomes and empowering health care professionals.

Let’s warmly welcome Christopher Bunick, Jeffrey Cohen, Giovanni Damiani, Victoria Guillano, Renata Magalhães, Eingun James Song, and Yi Xiao as they join the IPC Councilor community. Their addition underscores IPC’s commitment to driving positive change and improving global psoriasis care.

Christopher Bunick, MD, PhD

Yale University

New Haven, Connecticut, United States

IPC Councilor

Bio

Jeffrey Cohen, MD, MPH

Yale School of Medicine

New Haven, Connecticut, United States

IPC Councilor

Bio

Giovanni Damiani, MD, PhD

University of Milan

Milan, Italy

IPC Councilor

Bio

Victoria Patiño-Guillano, MD, FPDS, FDSP-PDS, MBA-H

University of Southeastern Philippines; DermPath Dermatology

Tagum, Philippines

IPC Councilor

Bio

Renata Ferreira Magalhães, MD, PhD

Unicamp Clinical Hospital

Campinas, Brazil

IPC Councilor

Bio

Eingun James Song, MD, FAAD

Frontier Dermatology

Mill Creek, Washington, United States

IPC Councilor

Bio

Yi Xiao, MD, PhD, MPH

Department of Dermatology, Xiangya Hospital, Central South University

Changsha, China

IPC Councilor

Bio

Comments are closed.

Categories

Recent Posts

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026